Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Neurofibromatosis type 1 is an autosomal dominant genetic disorder caused by pathogenic variants in the NF1 tumor-suppressor gene. NF1 occurs globally and nationally at a rate of approximately 1 in 3,000 individuals. Some global screening variations show ranges from 1 in 2,000 to 1 in 4,000 people depending on diagnostic criteria and reporting methods. According to Neurofibromatosis Type 1 Epidemiology Forecast by Expert Market Research (EMR), better registry coverage, standardized outcome reporting and longer-term treatment data would help quantify clinical need and evaluate access to emerging therapies.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Neurofibromatosis Type 1 – Number of Cases by Year

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Neurofibromatosis Type 1 Epidemiology Forecast Report Coverage

Expert Market Research's “Neurofibromatosis Type 1 Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Neurofibromatosis Type 1. It projects the future incidence and prevalence rates of Neurofibromatosis Type 1 cases across various populations. The study covers age, gender, and type as major determinants of the Neurofibromatosis Type 1 population. The report highlights patterns in the prevalence of Neurofibromatosis Type 1 over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Neurofibromatosis Type 1 in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Neurofibromatosis Type 1 Understanding: Disease Overview

Neurofibromatosis Type 1 (NF1), also known as von Recklinghausen disease, is a common multi-system genetic neurocutaneous disorder that affects skin pigmentation and causes the growth of benign (noncancerous) and occasionally malignant tumors along the nervous system. It affects approximately 1 in 2,500 to 3,000 people worldwide, with no preference for sex, race, or ethnicity. NF1 is caused by changes or pathogenic variants in the NF1 gene located on the long arm of chromosome 17 (17q11.2).

Key Report Insights

Parameter

Insight

Largest Patient Pool

India

Fastest Growing Country

United States

High-Risk Population

NF1 is a genetic condition rather than an infection acquired through a conventional environmental exposure. People with a parent carrying a pathogenic NF1 variant have an increased inherited risk, although new variants also occur.

Key Diagnostic Method

NF1 is diagnosed using established clinical criteria, supported by molecular genetic testing when needed. Assessment considers characteristic features such as multiple café-au-lait macules, axillary or inguinal freckling, neurofibromas, optic pathway glioma, specific ocular findings, characteristic bone lesions, an affected parent, or a pathogenic NF1 variant.

Major Risk Factor

The principal underlying risk factor is inheritance of a pathogenic NF1 variant from an affected parent; however, a substantial proportion of cases arise from new genetic variants. The severity and combination of manifestations vary considerably, including among members of the same family. For serious outcomes, clinically relevant risk factors include the presence and behaviour of plexiform neurofibromas, suspicious changes in tumour growth or pain, and other NF1-associated complications that warrant prompt assessment.

Major gap in the market

A major gap is the absence of comparable, recent national data on diagnosed and undiagnosed NF1 populations across all eight countries. This limits estimates of unmet need for genetic testing, specialist surveillance, surgery and targeted medicines.

Neurofibromatosis Type 1 Epidemiology Perspective

The Neurofibromatosis Type 1 epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Neurofibromatosis Type 1 epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Neurofibromatosis Type 1 and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

Neurofibromatosis Type 1 (NF1) is one of the most common autosomal dominant genetic disorders, with a globally recognized minimum prevalence estimated between 1 in 3,000 and 1 in 4,000 individuals in the general population. The condition has an annual incidence of approximately 1 in 2,500 to 1 in 3,000 live births worldwide, affecting all genders, races, and ethnicities equally.

Gender-Specific Cases of the Disease

From a statistical standpoint, Neurofibromatosis Type 1 (NF1) affects males and females equally, with a 1:1 prevalence and incidence ratio because it is an autosomal dominant condition mapping to the non-sex chromosome 17q11.2. While the incidence of developing an OPG is relatively similar between sexes, females are twice as likely to undergo brain MRIs for visual symptoms and three times more likely to require active treatment (such as chemotherapy) for severe visual decline.

Age-Specific Cases of the Disease

Documented prevalence reaches its peak density in childhood and adolescence, often reflecting active pediatric screening, family tracking when a parent is already diagnosed, and the emergence of visible diagnostic criteria like café-au-lait spots and freckling. Maxima analyses show the highest recorded active capture rates occurring before age 15.

Ethnicity-Wise Cases of the Disease

Neurofibromatosis Type 1 (NF1) affects all ethnic backgrounds and racial groups equally, maintaining a consistent baseline global prevalence of approximately 1 in 3,000 to 1 in 4,000 individuals worldwide. Because NF1 is an autosomal dominant genetic disorder caused by mutations on the non-sex chromosome 17q11.2, it has no known biological predilection for any specific race, culture, or geographic ancestry.

Mortality and Survival Analysis of the Disease

Neurofibromatosis Type 1 (NF1) significantly impacts life expectancy, reducing the average lifespan by 8 to 20 years compared to the general population. Large-scale population reviews establish the mean age of death for individuals with NF1 between 54.4 and 61.6 years, compared to an average of 70.1 to 74 years in the general public.

Neurofibromatosis Type 1 – Number of Cases by Country

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Country-wise Neurofibromatosis Type 1 Epidemiology

The Neurofibromatosis Type 1 epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

In the United States, Neurofibromatosis Type 1 (NF1) affects approximately 100,000 Americans, maintaining its position as one of the most common inherited neurogenetic syndromes nationwide. The disease conforms strictly to the global epidemiological baseline, presenting a stable domestic frequency of 1 in 3,000 to 1 in 3,500 people across the country.

Germany

In Germany, Neurofibromatosis Type 1 (NF1) affects approximately 30,000 individuals, adhering closely to the standard global birth incidence and prevalence benchmark of 1 in 2,600 to 1 in 3,000 newborns.

France

In France, Neurofibromatosis Type 1 (NF1) affects approximately 15,000 to 20,000 individuals, maintaining alignment with the standard global prevalence estimate of roughly 1 in 3,000 to 1 in 6,000 people.

Italy

In Italy, Neurofibromatosis Type 1 (NF1) affects an estimated 17,000 to 24,000 individuals, aligning closely with the globally established baseline birth incidence of 1 in 2,500 to 1 in 3,000 live births. A notable historical registry study conducted in Chieti (Abruzzi region) analyzing 21,181 young Italian male military recruits during premilitary medical evaluations documented a localized, actively screened clinical prevalence of roughly 1 in 5,735.

Spain

13,000 to 15,000 individuals are actively living with NF1 in Spain. Follows the global standard baseline of 1 in 2,500 to 1 in 3,000 live births. Among all diagnoses falling under the broader neurofibromatosis umbrella in Spain, NF1 accounts for 96% of all recorded cases (with the remainder consisting of rare NF2-related and non-NF2-related schwannomatoses).

United Kingdom

In the United Kingdom, Neurofibromatosis Type 1 (NF1) affects approximately 25,000 individuals, maintaining its status as one of the most common inherited neurocutaneous and tumor-predisposing syndromes across Britain. The disease tracks predictably with global data, exhibiting a domestic birth incidence of 1 in 2,500 to 1 in 3,300 live births and an active population prevalence calculated at roughly 1 in 4,560 individuals.

Japan

In Japan, Neurofibromatosis Type 1 (NF1) affects approximately 40,000 individuals, closely matching the globally established epidemiological frequency of 1 in 3,000 people. Within Japan's population of children aged 3 to 15 years, an estimated 4,300 children have NF1. While the majority of Japanese pediatric patients fall within the normal intelligence range (with a mean full IQ of 90.6), 6.2% present with concurrent intellectual disabilities, a rate threefold higher than the general Japanese pediatric population.

India

In India, Neurofibromatosis Type 1 (NF1) affects millions of individuals, conforming to the global estimated birth incidence of 1 in 2,500 to 3,300 live births. Population genetics literature indicates that roughly 93% of individuals of Indian origin carrying the trait manifest classical clinical symptoms, though nationwide centralized registries remain limited.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

Across the eight countries, the clearest unmet needs are more complete patient registries, timely genetic diagnosis, coordinated lifelong surveillance and equitable access to multidisciplinary care. Targeted treatment is an emerging area for symptomatic plexiform neurofibromas that cannot be adequately managed by surgery. Better reporting of patient numbers, treatment eligibility, response, adverse effects and long-term outcomes would support service planning and improve comparisons between countries. Current evidence does not support ranking the eight countries by prevalence growth.

Neurofibromatosis Type 1: Treatment Overview

NF1 management is individualized and focuses on surveillance, symptom control and treatment of specific complications. Surgery may be considered for selected neurofibromas, although complete resection of plexiform tumors can be difficult or carry substantial morbidity. MEK inhibitors are an important targeted-treatment development: the US FDA approved mirdametinib in February 2025 for adults and children aged two years and older with symptomatic plexiform neurofibromas not amenable to complete resection and expanded selumetinib indications in 2025 to include adults and younger pediatric patients. Regulatory indications differ by jurisdiction; eligibility, monitoring and treatment decisions require specialist assessment.

Key Questions Answered

  • What is the current and projected burden of Neurofibromatosis Type 1 across the 8 major markets?
  • Which countries across the 8 major markets account for the highest Neurofibromatosis Type 1 patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of Neurofibromatosis Type 1 across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of Neurofibromatosis Type 1 across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of Neurofibromatosis Type 1 across the 8 major markets?
  • How do major comorbidities and risk factors influence Neurofibromatosis Type 1 epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of Neurofibromatosis Type 1 across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the Neurofibromatosis Type 1 landscape across the 8 major markets?
  • Which therapeutic areas linked to Neurofibromatosis Type 1 are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the Neurofibromatosis Type 1 epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on Neurofibromatosis Type 1 epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for Neurofibromatosis Type 1 across the 8 major markets?

Scope of the Neurofibromatosis Type 1 Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Neurofibromatosis Type 1 based on several factors.
  • Neurofibromatosis Type 1 Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The Neurofibromatosis Type 1 report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Neurological Disease Treatment Market

Neurothrombectomy Devices Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us